Scientific Article
previous document  unige:10954  next document
add to browser collection

Recombinant interleukin-2 therapy of systemic lupus erythematosus in the New Zealand black/New Zealand white mouse

Owen, K. L.
Shibata, T.
Walker, S. E.
Published in Journal of Biological Response Modifiers. 1989, vol. 8, no. 4, p. 366-374
Abstract New Zealand Black/New Zealand White (NZB/W) mice, a model of systemic lupus erythematosus (SLE), have age-dependent loss of interleukin-2 (IL-2) production. To determine if replacement therapy would influence the course of autoimmune disease, we injected groups of NZB/W mice with low-dose (1,500 units/day) or high-dose (15,000 units/day) purified human recombinant IL-2. Parameters of active SLE and populations of splenocytes were not altered consistently by long-term treatment with either dose of IL-2.
Keywords AnimalsAutoantibodiesDisease Models, AnimalDose-Response Relationship, DrugFemaleFlow CytometryFluorescent Antibody TechniqueGlycoproteins/bloodHematologic TestsImmunoglobulins/analysisInterleukin-2/administration & dosage/ therapeutic useLupus Erythematosus, Systemic/ drug therapy/mortalityMaleMiceRecombinant Proteins/administration & dosage/therapeutic use
Stable URL
Full text
This document has no fulltext available yet, but you can contact its author by using the form below.
PMID: 2666586
138 hits and 0 download since 2010-08-26
Export document
Format :
Citation style :